375 related articles for article (PubMed ID: 19945005)
1. An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
Rubin M; Dover J; Maas C; Nestor M
Aesthet Surg J; 2009 Nov; 29(6 Suppl):S50-6. PubMed ID: 19945005
[TBL] [Abstract][Full Text] [Related]
2. An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
Baumann L; Brandt FS; Kane MA; Donofrio LM
Aesthet Surg J; 2009 Nov; 29(6 Suppl):S57-65. PubMed ID: 19945006
[TBL] [Abstract][Full Text] [Related]
3. An analysis of the long-term safety data of repeat administrations of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
Cohen JL; Schlessinger J; Cox SE; Lin X;
Aesthet Surg J; 2009 Nov; 29(6 Suppl):S43-9. PubMed ID: 19945004
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of neutralizing antibody induction during treatment of glabellar lines with a new US formulation of botulinum neurotoxin type A.
Lawrence I; Moy R
Aesthet Surg J; 2009 Nov; 29(6 Suppl):S66-71. PubMed ID: 19945007
[TBL] [Abstract][Full Text] [Related]
5. Botulinum neurotoxin type A-ABO (Dysport): clinical indications and practice guide.
Matarasso A; Shafer D
Aesthet Surg J; 2009 Nov; 29(6 Suppl):S72-9. PubMed ID: 19945008
[TBL] [Abstract][Full Text] [Related]
6. Time to onset of response of abobotulinumtoxina in the treatment of glabellar lines: a subset analysis of phase 3 clinical trials of a new botulinum toxin type A.
Schlessinger J; Monheit G; Kane MA; Mendelsohn N
Dermatol Surg; 2011 Oct; 37(10):1434-42. PubMed ID: 21745254
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study.
Wu Y; Fang F; Lai W; Li C; Li L; Liu Q; Lu J; Pang X; Sun J; Shi X; Picaut P; Prygova I; Andriopoulos B; Sun Q
Aesthetic Plast Surg; 2023 Feb; 47(1):351-364. PubMed ID: 36536093
[TBL] [Abstract][Full Text] [Related]
8. Safety, Tolerability, and Efficacy of Repeat-Dose Injections of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results from a Prospective, Open-Label, Phase III Study.
Fischer T; Sattler G; Prager W; Rzany B; Pavicic T; Gauglitz G; Weissenberger P; Riaz S
J Drugs Dermatol; 2020 May; 19(5):461-469. PubMed ID: 32484631
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study.
Monheit GD; Cohen JL;
J Am Acad Dermatol; 2009 Sep; 61(3):421-5. PubMed ID: 19577326
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines.
Moy R; Maas C; Monheit G; Huber MB;
Arch Facial Plast Surg; 2009; 11(2):77-83. PubMed ID: 19289677
[TBL] [Abstract][Full Text] [Related]
11. An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects.
Kawashima M; Harii K
Int J Dermatol; 2009 Jul; 48(7):768-76. PubMed ID: 19490208
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of variable-dose treatment with a new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study.
Kane MAC; Brandt F; Rohrich RJ; Narins RS; Monheit GD; Huber MB;
Plast Reconstr Surg; 2009 Nov; 124(5):1619-1629. PubMed ID: 19584772
[TBL] [Abstract][Full Text] [Related]
13. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety.
Brandt F; Swanson N; Baumann L; Huber B
Dermatol Surg; 2009 Dec; 35(12):1893-901. PubMed ID: 19549186
[TBL] [Abstract][Full Text] [Related]
14. A double-blind, randomized, placebo-controlled, two-dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects.
Harii K; Kawashima M
Aesthetic Plast Surg; 2008 Sep; 32(5):724-30. PubMed ID: 18663516
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety of abobotulinumtoxinA for the treatment of glabellar lines: results from a 36-month, multicenter, open-label extension study.
Schlessinger J; Dover JS; Joseph J; Monheit G; Nelson DB; Albright CD; Axford-Gatley RA; Cohen JL;
Dermatol Surg; 2014 Feb; 40(2):176-83. PubMed ID: 24372978
[TBL] [Abstract][Full Text] [Related]
16. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis.
Elkind AH; O'Carroll P; Blumenfeld A; DeGryse R; Dimitrova R;
J Pain; 2006 Oct; 7(10):688-96. PubMed ID: 17018329
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
18. Prior Botulinum Toxin Treatment Does Not Impact Efficacy or Safety in Clinical Trials: Analysis of DaxibotulinumtoxinA for Injection in the SAKURA Program.
Cohen JL; Green LJ; Beer KR; Liu Y; Gallagher CJ
Dermatol Surg; 2021 Apr; 47(4):511-515. PubMed ID: 33587381
[TBL] [Abstract][Full Text] [Related]
19. Does Increasing the Dose of Abobotulinumtoxina Impact the Duration of Effectiveness for the Treatment of Moderate to Severe Glabellar Lines?
Joseph JH; Eaton LL; Robinson J; Pontius A; Williams EF
J Drugs Dermatol; 2016 Dec; 15(12):1544-1549. PubMed ID: 29106437
[TBL] [Abstract][Full Text] [Related]
20. AbobotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines: A Randomized, Dose-Escalating, Double-Blind Study.
Joseph J; Moradi A; Lorenc ZP; Coleman K; Ablon G; Kaufman-Janette J; Cox SE; Campbell A; Dayan S; Berg AK; Munavalli G
J Drugs Dermatol; 2021 Sep; 20(9):980-987. PubMed ID: 34491016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
